Synthesis, structure and

Mohammed Boulhaoua, Tibor Pasinszki, Ana Torvisco, Rita Oláh-Szabó, Szilvia Bősze, Antal Csámpai

Open access · goldAbstract read

In one paragraph

Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.8field-weighted citation impact, top 33% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

Identification of a New Pentafluorosulfanyl-Substituted Chalcone with Activity Against Hepatoma and Human Parasites.Pharmaceuticals (Basel, Switzerland) · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Mohammed BoulhaouaELTE Eötvös Loránd University, Institute of Chemistry, Department of Inorganic Chemistry H-1117 Budapest Hungary.

Tibor PasinszkiFiji National University, College of Engineering Science and Technology, Department of Chemistry P.O.Box 3722, Samabula Suva Fiji tibor.pasinszki@fnu.ac.fj.ORCID https://orcid.org/0000-0001-7558-8230

Ana TorviscoGraz University of Technology, Institute of Inorganic Chemistry Stremayrgasse 9/V 8010 Graz Austria.

Rita Oláh-SzabóMTA-ELTE Research Group of Peptide Chemistry Pázmány P. sétány 1/A H-1117 Budapest Hungary.

Szilvia BőszeMTA-ELTE Research Group of Peptide Chemistry Pázmány P. sétány 1/A H-1117 Budapest Hungary.

Antal CsámpaiELTE Eötvös Loránd University, Institute of Chemistry, Department of Organic Chemistry H-1117 Budapest Hungary antal.csampai@ttk.elte.hu.ORCID https://orcid.org/0000-0003-2107-7309

Eötvös Loránd University · HUFiji National University · FJGraz University of Technology · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy is an indispensable tool to treat cancer, therefore, the development of new drugs that can treat cancer with minimal side effects and lead to more favorable prognoses is of crucial importance. A series of eleven novel 1,2,4-thiadiazoles bearing erlotinib (a known anticancer agent), phenylethynyl, ferrocenyl, and/or ferrocenethynyl moieties were synthesized in this work and characterized by NMR, IR and mass spectroscopies. The solid-phase structures were determined by single-crystal X-ray diffraction. Partial isomerisation of bis(erlotinib)-1,2,4-thiadiazole into its 1,3,4-thiadiazole isomer, leading to the isolation of a 3 : 2 isomer mixture, was observed and a plausible mechanism for isomerisation is suggested. The

Identifiers

PMID35478544

DOI10.1039/d1ra05095h

PMCPMC9038148

OpenAlexW3193632204

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.